Luther King Capital Management (LKCM)
IMUC

Luther King Capital Management (LKCM)’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Luther King Capital Management (LKCM)’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-250
Closed -$7K – 525
2016
Q3 		$7K Hold
250
– – ﹤0.01% 489
2016
Q2 		$7K Hold
250
– – ﹤0.01% 512
2016
Q1 		$7K Hold
250
– – ﹤0.01% 506
2015
Q4 		$4K Hold
250
– – ﹤0.01% 517
2015
Q3 		$4K Hold
250
– – ﹤0.01% 529
2015
Q2 		$7K Hold
250
– – ﹤0.01% 544
2015
Q1 		$7K Hold
250
– – ﹤0.01% 537
2014
Q4 		$7K Hold
250
– – ﹤0.01% 551
2014
Q3 		$9K Hold
250
– – ﹤0.01% 556
2014
Q2 		$11K Hold
250
– – ﹤0.01% 546
2014
Q1 		$12K Hold
250
– – ﹤0.01% 535
2013
Q4 		$9K Hold
250
– – ﹤0.01% 512
2013
Q3 		$26K Hold
250
– – ﹤0.01% 669
2013
Q2 		$19K Buy
+250
New +$23.9K ﹤0.01% 672

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $5.71M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return